HIV Prevention Research & Development Investments
In its 16th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group (“Working Group”) documents research and development spending for the calendar year 2020 and analyzes funding trends spanning twenty years.
US$
0
B
Funding for HIV Prevention Research & Development in 2020
The most up-to-date and comprehensive field-wide estimates for HIV prevention and R&D globally.
The Working Group’s 2020 analysis builds on the US$19 billion in funding tracked between 2000 and 2019 and underscores the importance of continued innovation in HIV prevention to bring a lasting end to the HIV/AIDS pandemic.
The biomedical HIV prevention options tracked include preventive AIDS vaccines, microbicides, prevention of vertical transmission (PMTCT), pre-exposure prophylaxis (PrEP), treatment as prevention (TasP), voluntary medical male circumcision (VMMC) and female condoms.
Funding At a Glance
What are the historic and current trends for investment in HIV prevention R&D?
For Year:
0
US$ Million
Preventative vaccines
0
US$ Million
Microbicides
0
US$ Million
Prevention of vertical transmission
0
US$ Million
Pre-exposure prophylaxis
0
US$ Million
Treatment as prevention
0
US$ Million
Voluntary medical male circumcision
0
US$ Million
Female Condoms
For Year:
0
US$ Million
Multilateral Public Sector
0
US$ Million
Europe - Public Sector
0
US$ Million
US Public Sector
0
US$ Million
Other Public Sector
0
US$ Million
Wellcome Trust
0
US$ Million
Bill & Melinda Gates Foundation
0
US$ Million
Other Philanthropic
0
US$ Million
Other Commercial
